- Home
- JQC vs TECX Comparison
JQC vs TECX Comparison
Compare JQC & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | JQC | TECX |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.4M | 371.0M |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | JQC | TECX |
|---|---|---|
| Price | $4.53 | $21.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $71.00 |
| AVG Volume (30 Days) | ★ 581.9K | 159.4K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.45 | $16.77 |
| 52 Week High | $5.18 | $39.53 |
Technical Indicators
Market Signals| Indicator | JQC | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 43.37 |
| Support Level | N/A | $18.54 |
| Resistance Level | $4.86 | $23.03 |
| Average True Range (ATR) | 0.07 | 1.25 |
| MACD | 0.00 | 0.36 |
| Stochastic Oscillator | 24.23 | 46.07 |
Price Performance
Historical ComparisonAbout JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The Fund mainly invests in senior loans, high-yield corporate debt, and collateralized loan obligation (CLO) debt.
About TECX Tectonic Therapeutic Inc.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.